The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
Last update: 04/11/2021
There are currently 26 open trials.
In 111 locations
What is a Clinical Trial?
There are currently 26 open trials
- Escalating doses of RO7425781 for relapsed and/or refractory myeloma
- CID-103 for Relapsed and/or Refractory Myeloma
- Belantamab mafodotin plus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-8)
- Isatuximab in combination with lenalidomide and dexamethasone for high-risk smouldering myeloma (ITHACA)
- Teclistamab combination treatments for myeloma
- Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIa)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIb)
- Teclistamab for relapsed and refractory myeloma
- JNJ-68284528 CART-cell therapy for relapsed and refractory myeloma
- Belantamab mafodotin with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma (DREAMM 9)
- Adaptive treatment in newly diagnosed myeloma patients not eligible for HDT-SCT (FiTNEss, Myeloma XIV)
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- Belantamab mafodotin versus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-3)
- A clinical trial evaluating RO5126766 for the treatment of refractory myeloma patients
- Understanding bone pain in myeloma
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- CC-92480 for relapsed and refractory multiple myeloma
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Escalating doses of RO7425781 for relapsed and/or refractory myeloma
Treatments:
RO7425781
Myeloma stage:
Relapsed, Refractory
Trial phase:
I
Summary:
This trial is investigating whether a drug called RO7425781 is safe and effective for the treatment of relapsed and/or refractory myeloma patients.
RO7425781 is a new type of immunotherapy being tested for the treatment of myeloma. It works by helping your immune cells find and kill myeloma cells.
The trial will consist of two parts.
Part A will test increasing doses to identify the best dose level, safety and efficacy.
Part B will use the results of optimum dosing from part A for a larger group of patients.
Locations:
University College Hospital, London
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have previously received treatment with an immunomodulatory agent, such as lenalidomide (Revlimid®), and a proteasome inhibitor such as bortezomib (Velcade®), and are now intolerant to standard-of-care treatment.
What's involved?:
Patients will be assigned to receive intravenous infusion (into the vein) or subcutaneous injection (under the skin) of RO7425781.
Different groups of patients will be given different doses of the drug.
Patients will be required to attend outpatient clinics for regular check-ups and blood tests. Patients will have to attend follow-up appointments for up to 69 weeks.
Clinical Information
(for Medical Professionals):
This is a first-in-human, open-label, uncontrolled, multicenter, dose-escalation and expansion Phase I study. The study is
designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of RO7425781 in patients with
relapsed/refractory myeloma, for whom no standard-of-care treatment exists or who are intolerant to those established
treatments.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk